Review



igm apc pj2 22h3 miltenyi  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Miltenyi Biotec igm apc pj2 22h3 miltenyi
    Igm Apc Pj2 22h3 Miltenyi, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/SARS-CoV-2+Spike+B+Cell+Analysis+Kit%2C+anti-human/pm42389809-268-167-170
    Average 97 stars, based on 13 article reviews
    igm apc pj2 22h3 miltenyi - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Cell Analysis:

    Article Title: Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination
    Article Snippet: .. The analysis of SARS-CoV-2-specific B-cells was performed using the SARS-CoV-2 Spike B Cell Analysis Kit, anti-human (Miltenyi Biotec). ..

    Article Title: Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors
    Article Snippet: .. Spike-specific memory B cells were detected by SARS-CoV-2 spike B cell Analysis kit (Miltenyi Biotec cat. no. 130-128-022), according to manufacturer’s instructions. ..

    Article Title: Longitudinal Evaluation of Humoral and Cellular Immunity After BNT162b2 COVID-19 Vaccination: Influence of Booster Type, Infection and Chronic Health Conditions.
    Article Snippet: .. The SARS-CoV-2 Spike B Cell Analysis Kit was used to analyzespecific Spike antibodies expressed by human B-cells (Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach; Germany). ..

    Article Title: Longitudinal Evaluation of Humoral and Cellular Immunity After BNT162b2 COVID-19 Vaccination: Influence of Booster Type, Infection and Chronic Health Conditions
    Article Snippet: .. The SARS-CoV-2 Spike B Cell Analysis Kit was used to analyzespecific Spike antibodies expressed by human B-cells (Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach; Germany). ..

    Article Title: Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination.
    Article Snippet: .. 2.5 Quantification of SARS-CoV-2 specific B-cells The analysis of SARS-CoV-2-specific B-cells was performed using the SARS-CoV-2 Spike B Cell Analysis Kit, anti-human (Miltenyi Biotec). ..

    Article Title: GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti human CD19 conjugated to APC-Vio770 (clone LT19) Miltenyi Biotec Cat# 130-113-166; RRID: AB_2725994 mouse anti human CD27 conjugated to Vio Bright FITC (clone M-T271) Miltenyi Biotec Cat# 130-113-634; RRID: AB_2751160 mouse anti human IgA conjugated to VioGreen (clone IS11-8E10) Miltenyi Biotec Cat# 130-113-481; RRID: AB_2734099 mouse anti human IgM conjugated to APC (clone Pj2-22H3) Miltenyi Biotec Cat# 130-122-915; RRID: AB_2801965 mouse anti human IgG conjugated to VioBlue (clone IS11-3B2.2.3) Miltenyi Biotec Cat# 130-119-881; RRID: AB_2751904 mouse anti human CD24 conjugated to BV711 (clone ML5) BD Biosciences Cat# 563401; RRID: AB_2631261 mouse anti human CD107a conjugated to PE-CF594 (clone H4A3) BD Biosciences Cat# 562628; RRID: AB_2737686 mouse anti human CD3 conjugated to BUV395 (clone UCHT1) BD Biosciences Cat# 563546; RRID: AB_2744387 mouse anti human CD4 conjugated to BUV737 clone SK3 BD Biosciences Cat# 612748; RRID: AB_2870079 mouse anti human CD8 conjugated to BV605 (clone SK1) BD Biosciences Cat# 564116; RRID: AB_2869551 mouse anti human CD154 conjugated to BB700 (clone TRAP1) BD Biosciences Cat# 745814; RRID: AB_2743265 mouse anti human IFNg conjugated to APC clone B27 BD Biosciences Cat# 554702; RRID: AB_398580 rat anti human IL-2 conjugated to PE (clone mQ1-17H12) BD Biosciences Cat# 559334; RRID: AB_397231 mouse anti human TNFa conjugated to BV650 (clone Mab11) BD Biosciences Cat# 563418; RRID: AB_2738194 mouse anti human CD69 conjugated to APC-R700 (clone FN50) BD Biosciences Cat# 565154; RRID: AB_2744449 Biological samples Human Serum Study Participants N/A Human PBMC Study Participants N/A Chemicals, peptides, and recombinant proteins PepMixTM SARS-CoV-2 (Spike Glycoprotein) JPT Cat# PM-WCPV-S-1 PepMixTM SARS-CoV-2 (Spike B.1.617.2/ Delta) JPT Cat# PM-SARS2-SMUT06-1 PepMixTM SARS-CoV-2 (Spike B.1.1.529/ BA.1/Omicron) JPT Cat# PM-SARS2-SMUT08-1 CEFX Ultra SuperStim Pool JPT Cat# PM-CEFX-1 Overlapping SARS-CoV-2 Spike 15mers custom ordered from Elabscience Biotech Inc (Lanini S. et al., SciTraslMed 2021) N/A, Staphylococcal enterotoxin B from Staphylococcus aureus Sigma-Aldrich Cat# S4881 GolgiPlug BD Biosciences Cat# 555029 (Continued on next page) e1 Cell Reports Medicine 4, 101084, June 20, 2023 .. REAGENT or RESOURCE SOURCE IDENTIFIER Brilliant Stain Buffer BD Biosciences Cat# 563794 BD Fixation/Permeabilization Kit BD Biosciences Cat# 554714 FVS780 BD Biosciences Cat# 565388 HyClone Defined FBS, US Origin, 500 mL Cytiva Cat# SH30070.03 CTL-WashTM Supplement 10x Immunospot Cat# CTLW-010 CellTrace Violet ThermoFisher Cat# C34571 Critical commercial assays COVID-SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit (Spike) R&D Systems Cat# DSR200 ARCHITECT SARS-CoV-2 IgG kit (Nucleocapsid) Abbot Cat# 6R86 ARCHITECT SARS-CoV-2 IgG II Quant (RBD) Abbot Cat# 6S60 Human IFN-g ELISpot plus kit Mabtech Cat# 3420-4APT IFNg-IL5 Fluorospot Mabtech Cat# FSP-0108 SARS-CoV-2 Spike B cell analysis kit Miltenyi Biotec Cat# 130-128-022 SARS-CoV-2 live neutralization assay Viroclinics Biosciences-Cerba N/A Pseudo-neutralization assay (D614 and D strains) Nexelis-Q2 solutions https://nexelis.com/our-expertise/ infectious-diseases/covid-19/ Pseudo-neutralization assay (D614) Monogram Biosciences-Labcorp https://monogrambio.labcorp.com/ phenosense-sars-cov-2neutralizing-antibody Software and algorithms Graphpad PRISM 7 GraphPad RRID:SCR_002798 FlowJo 10 BD Biosciences RRID:SCR_008520 SAS System software 9.4 SAS Institute Inc. RRID:SCR_008567 CTL Immunospot suite 2.7 Cellular Technology Limited RRID:SCR_011082 SPICE 6 NIH/NIAID https://niaid.github.io/spice/ RRID:SCR_016603 Article ll OPEN ACCESS .. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Stefania Capone (Stefania.capone@reithera.com).

    Recombinase Polymerase Amplification:

    Article Title: Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec.
    Article Snippet: .. Antibody target (eventual alias in brackets) Fluorochrome Clone Company Catalog # CD127 BB700 HIL-7R-M21 BD 566398 CD137 (41BB) BUV615 4B4-1 LIGAND BD 751492 CD183 (CXCR3) PECY7 1C6/CXCR3 BD 560831 CD185 (CXCR5) APC-CY7 J252D4 BioLegend 356926 CD19 APC-Vio 770 LT19 Miltenyi 130-128- 022 CD195 (CCR5) FITC HEK/1/85a BioLegend 313705 CD196 (CCR6) APCR700 11A9 BD 565173 CD197 (CCR7) BV711 150503 BD 566602 CD21 PECY5 B-ly4 BD 551064 CD138 Pe-CF594 MI15 BD 564606 CD25 Pecy5 M-A251 BD 555433 CD27 BUV737 L128 BD 564301 CD27 Vio Bright FITC M-T271 Miltenyi 130-128- 022 CD279 (PD1) BV650 EH12.1 BD 564104 CD3 BUV 805 UCHT1 BD 612895 CD4 BUV 395 SK3 BD 563550 CD4 BUV737 SK3 BD 612748 CD40L PECY5 cl.24-31 BioLegend 310808 CD45RA BUV496 HI100 BD 750258 CD45RO BV605 UCHL1 BD 562791 CD69 BV650 FN50 BD 563835 CD8 BUV 563 RPA-T8 BD 612914 FOXP3 PE-CF594 259D/C7 BD 562421 GRANZYME B BV421 GB 11 BD 563389 GRANZYME K Alexa Fluor647 G3H69 BD 566655 IgD BV480 IA6-2 BD 566138 IgG VioBlue IS113B2.2.3 Miltenyi 130-128- 022 IgM APC PJ2-22H3 Miltenyi 130-128- 022 LIVE AND DEAD FIX VIAB 780 - BD 565388 LIVE AND DEAD Aqua - thermofisher L34957 ..

    Staining:

    Article Title: GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti human CD19 conjugated to APC-Vio770 (clone LT19) Miltenyi Biotec Cat# 130-113-166; RRID: AB_2725994 mouse anti human CD27 conjugated to Vio Bright FITC (clone M-T271) Miltenyi Biotec Cat# 130-113-634; RRID: AB_2751160 mouse anti human IgA conjugated to VioGreen (clone IS11-8E10) Miltenyi Biotec Cat# 130-113-481; RRID: AB_2734099 mouse anti human IgM conjugated to APC (clone Pj2-22H3) Miltenyi Biotec Cat# 130-122-915; RRID: AB_2801965 mouse anti human IgG conjugated to VioBlue (clone IS11-3B2.2.3) Miltenyi Biotec Cat# 130-119-881; RRID: AB_2751904 mouse anti human CD24 conjugated to BV711 (clone ML5) BD Biosciences Cat# 563401; RRID: AB_2631261 mouse anti human CD107a conjugated to PE-CF594 (clone H4A3) BD Biosciences Cat# 562628; RRID: AB_2737686 mouse anti human CD3 conjugated to BUV395 (clone UCHT1) BD Biosciences Cat# 563546; RRID: AB_2744387 mouse anti human CD4 conjugated to BUV737 clone SK3 BD Biosciences Cat# 612748; RRID: AB_2870079 mouse anti human CD8 conjugated to BV605 (clone SK1) BD Biosciences Cat# 564116; RRID: AB_2869551 mouse anti human CD154 conjugated to BB700 (clone TRAP1) BD Biosciences Cat# 745814; RRID: AB_2743265 mouse anti human IFNg conjugated to APC clone B27 BD Biosciences Cat# 554702; RRID: AB_398580 rat anti human IL-2 conjugated to PE (clone mQ1-17H12) BD Biosciences Cat# 559334; RRID: AB_397231 mouse anti human TNFa conjugated to BV650 (clone Mab11) BD Biosciences Cat# 563418; RRID: AB_2738194 mouse anti human CD69 conjugated to APC-R700 (clone FN50) BD Biosciences Cat# 565154; RRID: AB_2744449 Biological samples Human Serum Study Participants N/A Human PBMC Study Participants N/A Chemicals, peptides, and recombinant proteins PepMixTM SARS-CoV-2 (Spike Glycoprotein) JPT Cat# PM-WCPV-S-1 PepMixTM SARS-CoV-2 (Spike B.1.617.2/ Delta) JPT Cat# PM-SARS2-SMUT06-1 PepMixTM SARS-CoV-2 (Spike B.1.1.529/ BA.1/Omicron) JPT Cat# PM-SARS2-SMUT08-1 CEFX Ultra SuperStim Pool JPT Cat# PM-CEFX-1 Overlapping SARS-CoV-2 Spike 15mers custom ordered from Elabscience Biotech Inc (Lanini S. et al., SciTraslMed 2021) N/A, Staphylococcal enterotoxin B from Staphylococcus aureus Sigma-Aldrich Cat# S4881 GolgiPlug BD Biosciences Cat# 555029 (Continued on next page) e1 Cell Reports Medicine 4, 101084, June 20, 2023 .. REAGENT or RESOURCE SOURCE IDENTIFIER Brilliant Stain Buffer BD Biosciences Cat# 563794 BD Fixation/Permeabilization Kit BD Biosciences Cat# 554714 FVS780 BD Biosciences Cat# 565388 HyClone Defined FBS, US Origin, 500 mL Cytiva Cat# SH30070.03 CTL-WashTM Supplement 10x Immunospot Cat# CTLW-010 CellTrace Violet ThermoFisher Cat# C34571 Critical commercial assays COVID-SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit (Spike) R&D Systems Cat# DSR200 ARCHITECT SARS-CoV-2 IgG kit (Nucleocapsid) Abbot Cat# 6R86 ARCHITECT SARS-CoV-2 IgG II Quant (RBD) Abbot Cat# 6S60 Human IFN-g ELISpot plus kit Mabtech Cat# 3420-4APT IFNg-IL5 Fluorospot Mabtech Cat# FSP-0108 SARS-CoV-2 Spike B cell analysis kit Miltenyi Biotec Cat# 130-128-022 SARS-CoV-2 live neutralization assay Viroclinics Biosciences-Cerba N/A Pseudo-neutralization assay (D614 and D strains) Nexelis-Q2 solutions https://nexelis.com/our-expertise/ infectious-diseases/covid-19/ Pseudo-neutralization assay (D614) Monogram Biosciences-Labcorp https://monogrambio.labcorp.com/ phenosense-sars-cov-2neutralizing-antibody Software and algorithms Graphpad PRISM 7 GraphPad RRID:SCR_002798 FlowJo 10 BD Biosciences RRID:SCR_008520 SAS System software 9.4 SAS Institute Inc. RRID:SCR_008567 CTL Immunospot suite 2.7 Cellular Technology Limited RRID:SCR_011082 SPICE 6 NIH/NIAID https://niaid.github.io/spice/ RRID:SCR_016603 Article ll OPEN ACCESS .. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Stefania Capone (Stefania.capone@reithera.com).

    Enzyme-linked Immunospot:

    Article Title: GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti human CD19 conjugated to APC-Vio770 (clone LT19) Miltenyi Biotec Cat# 130-113-166; RRID: AB_2725994 mouse anti human CD27 conjugated to Vio Bright FITC (clone M-T271) Miltenyi Biotec Cat# 130-113-634; RRID: AB_2751160 mouse anti human IgA conjugated to VioGreen (clone IS11-8E10) Miltenyi Biotec Cat# 130-113-481; RRID: AB_2734099 mouse anti human IgM conjugated to APC (clone Pj2-22H3) Miltenyi Biotec Cat# 130-122-915; RRID: AB_2801965 mouse anti human IgG conjugated to VioBlue (clone IS11-3B2.2.3) Miltenyi Biotec Cat# 130-119-881; RRID: AB_2751904 mouse anti human CD24 conjugated to BV711 (clone ML5) BD Biosciences Cat# 563401; RRID: AB_2631261 mouse anti human CD107a conjugated to PE-CF594 (clone H4A3) BD Biosciences Cat# 562628; RRID: AB_2737686 mouse anti human CD3 conjugated to BUV395 (clone UCHT1) BD Biosciences Cat# 563546; RRID: AB_2744387 mouse anti human CD4 conjugated to BUV737 clone SK3 BD Biosciences Cat# 612748; RRID: AB_2870079 mouse anti human CD8 conjugated to BV605 (clone SK1) BD Biosciences Cat# 564116; RRID: AB_2869551 mouse anti human CD154 conjugated to BB700 (clone TRAP1) BD Biosciences Cat# 745814; RRID: AB_2743265 mouse anti human IFNg conjugated to APC clone B27 BD Biosciences Cat# 554702; RRID: AB_398580 rat anti human IL-2 conjugated to PE (clone mQ1-17H12) BD Biosciences Cat# 559334; RRID: AB_397231 mouse anti human TNFa conjugated to BV650 (clone Mab11) BD Biosciences Cat# 563418; RRID: AB_2738194 mouse anti human CD69 conjugated to APC-R700 (clone FN50) BD Biosciences Cat# 565154; RRID: AB_2744449 Biological samples Human Serum Study Participants N/A Human PBMC Study Participants N/A Chemicals, peptides, and recombinant proteins PepMixTM SARS-CoV-2 (Spike Glycoprotein) JPT Cat# PM-WCPV-S-1 PepMixTM SARS-CoV-2 (Spike B.1.617.2/ Delta) JPT Cat# PM-SARS2-SMUT06-1 PepMixTM SARS-CoV-2 (Spike B.1.1.529/ BA.1/Omicron) JPT Cat# PM-SARS2-SMUT08-1 CEFX Ultra SuperStim Pool JPT Cat# PM-CEFX-1 Overlapping SARS-CoV-2 Spike 15mers custom ordered from Elabscience Biotech Inc (Lanini S. et al., SciTraslMed 2021) N/A, Staphylococcal enterotoxin B from Staphylococcus aureus Sigma-Aldrich Cat# S4881 GolgiPlug BD Biosciences Cat# 555029 (Continued on next page) e1 Cell Reports Medicine 4, 101084, June 20, 2023 .. REAGENT or RESOURCE SOURCE IDENTIFIER Brilliant Stain Buffer BD Biosciences Cat# 563794 BD Fixation/Permeabilization Kit BD Biosciences Cat# 554714 FVS780 BD Biosciences Cat# 565388 HyClone Defined FBS, US Origin, 500 mL Cytiva Cat# SH30070.03 CTL-WashTM Supplement 10x Immunospot Cat# CTLW-010 CellTrace Violet ThermoFisher Cat# C34571 Critical commercial assays COVID-SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit (Spike) R&D Systems Cat# DSR200 ARCHITECT SARS-CoV-2 IgG kit (Nucleocapsid) Abbot Cat# 6R86 ARCHITECT SARS-CoV-2 IgG II Quant (RBD) Abbot Cat# 6S60 Human IFN-g ELISpot plus kit Mabtech Cat# 3420-4APT IFNg-IL5 Fluorospot Mabtech Cat# FSP-0108 SARS-CoV-2 Spike B cell analysis kit Miltenyi Biotec Cat# 130-128-022 SARS-CoV-2 live neutralization assay Viroclinics Biosciences-Cerba N/A Pseudo-neutralization assay (D614 and D strains) Nexelis-Q2 solutions https://nexelis.com/our-expertise/ infectious-diseases/covid-19/ Pseudo-neutralization assay (D614) Monogram Biosciences-Labcorp https://monogrambio.labcorp.com/ phenosense-sars-cov-2neutralizing-antibody Software and algorithms Graphpad PRISM 7 GraphPad RRID:SCR_002798 FlowJo 10 BD Biosciences RRID:SCR_008520 SAS System software 9.4 SAS Institute Inc. RRID:SCR_008567 CTL Immunospot suite 2.7 Cellular Technology Limited RRID:SCR_011082 SPICE 6 NIH/NIAID https://niaid.github.io/spice/ RRID:SCR_016603 Article ll OPEN ACCESS .. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Stefania Capone (Stefania.capone@reithera.com).

    Neutralization:

    Article Title: GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti human CD19 conjugated to APC-Vio770 (clone LT19) Miltenyi Biotec Cat# 130-113-166; RRID: AB_2725994 mouse anti human CD27 conjugated to Vio Bright FITC (clone M-T271) Miltenyi Biotec Cat# 130-113-634; RRID: AB_2751160 mouse anti human IgA conjugated to VioGreen (clone IS11-8E10) Miltenyi Biotec Cat# 130-113-481; RRID: AB_2734099 mouse anti human IgM conjugated to APC (clone Pj2-22H3) Miltenyi Biotec Cat# 130-122-915; RRID: AB_2801965 mouse anti human IgG conjugated to VioBlue (clone IS11-3B2.2.3) Miltenyi Biotec Cat# 130-119-881; RRID: AB_2751904 mouse anti human CD24 conjugated to BV711 (clone ML5) BD Biosciences Cat# 563401; RRID: AB_2631261 mouse anti human CD107a conjugated to PE-CF594 (clone H4A3) BD Biosciences Cat# 562628; RRID: AB_2737686 mouse anti human CD3 conjugated to BUV395 (clone UCHT1) BD Biosciences Cat# 563546; RRID: AB_2744387 mouse anti human CD4 conjugated to BUV737 clone SK3 BD Biosciences Cat# 612748; RRID: AB_2870079 mouse anti human CD8 conjugated to BV605 (clone SK1) BD Biosciences Cat# 564116; RRID: AB_2869551 mouse anti human CD154 conjugated to BB700 (clone TRAP1) BD Biosciences Cat# 745814; RRID: AB_2743265 mouse anti human IFNg conjugated to APC clone B27 BD Biosciences Cat# 554702; RRID: AB_398580 rat anti human IL-2 conjugated to PE (clone mQ1-17H12) BD Biosciences Cat# 559334; RRID: AB_397231 mouse anti human TNFa conjugated to BV650 (clone Mab11) BD Biosciences Cat# 563418; RRID: AB_2738194 mouse anti human CD69 conjugated to APC-R700 (clone FN50) BD Biosciences Cat# 565154; RRID: AB_2744449 Biological samples Human Serum Study Participants N/A Human PBMC Study Participants N/A Chemicals, peptides, and recombinant proteins PepMixTM SARS-CoV-2 (Spike Glycoprotein) JPT Cat# PM-WCPV-S-1 PepMixTM SARS-CoV-2 (Spike B.1.617.2/ Delta) JPT Cat# PM-SARS2-SMUT06-1 PepMixTM SARS-CoV-2 (Spike B.1.1.529/ BA.1/Omicron) JPT Cat# PM-SARS2-SMUT08-1 CEFX Ultra SuperStim Pool JPT Cat# PM-CEFX-1 Overlapping SARS-CoV-2 Spike 15mers custom ordered from Elabscience Biotech Inc (Lanini S. et al., SciTraslMed 2021) N/A, Staphylococcal enterotoxin B from Staphylococcus aureus Sigma-Aldrich Cat# S4881 GolgiPlug BD Biosciences Cat# 555029 (Continued on next page) e1 Cell Reports Medicine 4, 101084, June 20, 2023 .. REAGENT or RESOURCE SOURCE IDENTIFIER Brilliant Stain Buffer BD Biosciences Cat# 563794 BD Fixation/Permeabilization Kit BD Biosciences Cat# 554714 FVS780 BD Biosciences Cat# 565388 HyClone Defined FBS, US Origin, 500 mL Cytiva Cat# SH30070.03 CTL-WashTM Supplement 10x Immunospot Cat# CTLW-010 CellTrace Violet ThermoFisher Cat# C34571 Critical commercial assays COVID-SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit (Spike) R&D Systems Cat# DSR200 ARCHITECT SARS-CoV-2 IgG kit (Nucleocapsid) Abbot Cat# 6R86 ARCHITECT SARS-CoV-2 IgG II Quant (RBD) Abbot Cat# 6S60 Human IFN-g ELISpot plus kit Mabtech Cat# 3420-4APT IFNg-IL5 Fluorospot Mabtech Cat# FSP-0108 SARS-CoV-2 Spike B cell analysis kit Miltenyi Biotec Cat# 130-128-022 SARS-CoV-2 live neutralization assay Viroclinics Biosciences-Cerba N/A Pseudo-neutralization assay (D614 and D strains) Nexelis-Q2 solutions https://nexelis.com/our-expertise/ infectious-diseases/covid-19/ Pseudo-neutralization assay (D614) Monogram Biosciences-Labcorp https://monogrambio.labcorp.com/ phenosense-sars-cov-2neutralizing-antibody Software and algorithms Graphpad PRISM 7 GraphPad RRID:SCR_002798 FlowJo 10 BD Biosciences RRID:SCR_008520 SAS System software 9.4 SAS Institute Inc. RRID:SCR_008567 CTL Immunospot suite 2.7 Cellular Technology Limited RRID:SCR_011082 SPICE 6 NIH/NIAID https://niaid.github.io/spice/ RRID:SCR_016603 Article ll OPEN ACCESS .. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Stefania Capone (Stefania.capone@reithera.com).

    Software:

    Article Title: GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti human CD19 conjugated to APC-Vio770 (clone LT19) Miltenyi Biotec Cat# 130-113-166; RRID: AB_2725994 mouse anti human CD27 conjugated to Vio Bright FITC (clone M-T271) Miltenyi Biotec Cat# 130-113-634; RRID: AB_2751160 mouse anti human IgA conjugated to VioGreen (clone IS11-8E10) Miltenyi Biotec Cat# 130-113-481; RRID: AB_2734099 mouse anti human IgM conjugated to APC (clone Pj2-22H3) Miltenyi Biotec Cat# 130-122-915; RRID: AB_2801965 mouse anti human IgG conjugated to VioBlue (clone IS11-3B2.2.3) Miltenyi Biotec Cat# 130-119-881; RRID: AB_2751904 mouse anti human CD24 conjugated to BV711 (clone ML5) BD Biosciences Cat# 563401; RRID: AB_2631261 mouse anti human CD107a conjugated to PE-CF594 (clone H4A3) BD Biosciences Cat# 562628; RRID: AB_2737686 mouse anti human CD3 conjugated to BUV395 (clone UCHT1) BD Biosciences Cat# 563546; RRID: AB_2744387 mouse anti human CD4 conjugated to BUV737 clone SK3 BD Biosciences Cat# 612748; RRID: AB_2870079 mouse anti human CD8 conjugated to BV605 (clone SK1) BD Biosciences Cat# 564116; RRID: AB_2869551 mouse anti human CD154 conjugated to BB700 (clone TRAP1) BD Biosciences Cat# 745814; RRID: AB_2743265 mouse anti human IFNg conjugated to APC clone B27 BD Biosciences Cat# 554702; RRID: AB_398580 rat anti human IL-2 conjugated to PE (clone mQ1-17H12) BD Biosciences Cat# 559334; RRID: AB_397231 mouse anti human TNFa conjugated to BV650 (clone Mab11) BD Biosciences Cat# 563418; RRID: AB_2738194 mouse anti human CD69 conjugated to APC-R700 (clone FN50) BD Biosciences Cat# 565154; RRID: AB_2744449 Biological samples Human Serum Study Participants N/A Human PBMC Study Participants N/A Chemicals, peptides, and recombinant proteins PepMixTM SARS-CoV-2 (Spike Glycoprotein) JPT Cat# PM-WCPV-S-1 PepMixTM SARS-CoV-2 (Spike B.1.617.2/ Delta) JPT Cat# PM-SARS2-SMUT06-1 PepMixTM SARS-CoV-2 (Spike B.1.1.529/ BA.1/Omicron) JPT Cat# PM-SARS2-SMUT08-1 CEFX Ultra SuperStim Pool JPT Cat# PM-CEFX-1 Overlapping SARS-CoV-2 Spike 15mers custom ordered from Elabscience Biotech Inc (Lanini S. et al., SciTraslMed 2021) N/A, Staphylococcal enterotoxin B from Staphylococcus aureus Sigma-Aldrich Cat# S4881 GolgiPlug BD Biosciences Cat# 555029 (Continued on next page) e1 Cell Reports Medicine 4, 101084, June 20, 2023 .. REAGENT or RESOURCE SOURCE IDENTIFIER Brilliant Stain Buffer BD Biosciences Cat# 563794 BD Fixation/Permeabilization Kit BD Biosciences Cat# 554714 FVS780 BD Biosciences Cat# 565388 HyClone Defined FBS, US Origin, 500 mL Cytiva Cat# SH30070.03 CTL-WashTM Supplement 10x Immunospot Cat# CTLW-010 CellTrace Violet ThermoFisher Cat# C34571 Critical commercial assays COVID-SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit (Spike) R&D Systems Cat# DSR200 ARCHITECT SARS-CoV-2 IgG kit (Nucleocapsid) Abbot Cat# 6R86 ARCHITECT SARS-CoV-2 IgG II Quant (RBD) Abbot Cat# 6S60 Human IFN-g ELISpot plus kit Mabtech Cat# 3420-4APT IFNg-IL5 Fluorospot Mabtech Cat# FSP-0108 SARS-CoV-2 Spike B cell analysis kit Miltenyi Biotec Cat# 130-128-022 SARS-CoV-2 live neutralization assay Viroclinics Biosciences-Cerba N/A Pseudo-neutralization assay (D614 and D strains) Nexelis-Q2 solutions https://nexelis.com/our-expertise/ infectious-diseases/covid-19/ Pseudo-neutralization assay (D614) Monogram Biosciences-Labcorp https://monogrambio.labcorp.com/ phenosense-sars-cov-2neutralizing-antibody Software and algorithms Graphpad PRISM 7 GraphPad RRID:SCR_002798 FlowJo 10 BD Biosciences RRID:SCR_008520 SAS System software 9.4 SAS Institute Inc. RRID:SCR_008567 CTL Immunospot suite 2.7 Cellular Technology Limited RRID:SCR_011082 SPICE 6 NIH/NIAID https://niaid.github.io/spice/ RRID:SCR_016603 Article ll OPEN ACCESS .. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Stefania Capone (Stefania.capone@reithera.com).



    Similar Products

    97
    Sino Biological sars cov np
    (A) Detection <t>of</t> <t>SARS-CoV-2</t> infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Sars Cov Np, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/SARS-CoV+SARS-CoV-2+Nucleocapsid+Antibody%2C+Rabbit+MAb/pmc13657315-66-12-14
    Average 97 stars, based on 1 article reviews
    sars cov np - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    94
    Native Antigen Inc rec31851
    (A) Detection <t>of</t> <t>SARS-CoV-2</t> infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Rec31851, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/SARS-CoV-2+Nucleoprotein%2C+His-Tag+(E%2E+coli)/pm42813529-65-61-58
    Average 94 stars, based on 1 article reviews
    rec31851 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    86
    Roche roche s elecsys anti sars cov 2 assay
    (A) Detection <t>of</t> <t>SARS-CoV-2</t> infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Roche S Elecsys Anti Sars Cov 2 Assay, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/nct05582512-29-17-21
    Average 86 stars, based on 1 article reviews
    roche s elecsys anti sars cov 2 assay - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Acon Biotech Hangzhou Co Ltd sars cov 2 nucleocapsid by immunochromatography
    (A) Detection <t>of</t> <t>SARS-CoV-2</t> infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Sars Cov 2 Nucleocapsid By Immunochromatography, supplied by Acon Biotech Hangzhou Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/pm42035785-87-10-14
    Average 86 stars, based on 1 article reviews
    sars cov 2 nucleocapsid by immunochromatography - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    96
    Sino Biological primary rabbit mab antibody
    (A) Detection <t>of</t> <t>SARS-CoV-2</t> infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Primary Rabbit Mab Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/SARS-CoV+%2F+SARS-CoV-2+Nucleocapsid+Antibody%2C+Rabbit+MAb/pmc13657315-66-6-14
    Average 96 stars, based on 1 article reviews
    primary rabbit mab antibody - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Sino Biological rabbit anti sars cov np
    (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green <t>(anti-SARS-CoV</t> NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Rabbit Anti Sars Cov Np, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/SARS-CoV+SARS-CoV-2+Spike+Antibody%2C+Rabbit+MAb/pmc13657315-78-9-12
    Average 96 stars, based on 1 article reviews
    rabbit anti sars cov np - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    93
    Sino Biological rabbit monoclonal antibody
    (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green <t>(anti-SARS-CoV</t> NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Rabbit Monoclonal Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/SARS-CoV+%2F+SARS-CoV-2+Nucleocapsid+Antibody%2C+Rabbit+MAb/pmc13657315-58-6-15
    Average 93 stars, based on 1 article reviews
    rabbit monoclonal antibody - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    BPS Bioscience uorogenic förster resonance energy transfer fret substrate
    (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green <t>(anti-SARS-CoV</t> NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Uorogenic Förster Resonance Energy Transfer Fret Substrate, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/3CL+Protease+(SARS-CoV-1+%2F+SARS-CoV-2)+Substrate/pm42835829-149-9-22
    Average 93 stars, based on 1 article reviews
    uorogenic förster resonance energy transfer fret substrate - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    BPS Bioscience fluorescence based assay kit
    (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green <t>(anti-SARS-CoV</t> NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Fluorescence Based Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/Papain-like+Protease+(SARS-CoV-2)+Assay+Kit%3A+Protease+Activity/10__25259_slash_jksus_15_2026-177-9-12
    Average 93 stars, based on 1 article reviews
    fluorescence based assay kit - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    95
    Sino Biological chimeric monoclonal antibody
    (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green <t>(anti-SARS-CoV</t> NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.
    Chimeric Monoclonal Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov+/SARS-CoV-2+(2019-nCoV)+Spike+S2+Antibody%2C+Chimeric+MAb/pm42813529-60-12-15
    Average 95 stars, based on 1 article reviews
    chimeric monoclonal antibody - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Journal: PLOS One

    Article Title: Omicron SARS-CoV-2 shows NRP1-linked susceptibility in adipose-derived MSCs and alters primitive cord blood CD34⁺ HSPCs

    doi: 10.1371/journal.pone.0360439

    Figure Lengend Snippet: (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Article Snippet: To stain the viral NP, a primary rabbit mAb antibody specific for SARS-CoV NP (Sino Biological Inc.) was used at a dilution ratio of 1:1000.

    Techniques: Infection, Imaging, Control, Flow Cytometry, Analysis, Focus Forming Assay, RNA Extraction, Expressing, Real-time Polymerase Chain Reaction

    (A) Representative western blot depicting the expression of NRP1 in AD-MSCs (No siRNA), cells transfected with non-targeting siRNA (siControl), or siNRP1 for 24 hours. β-actin was used as a loading control. (B) Graph displaying the quantification of NRP1 normalized to β-actin (n = 3). This experiment represents three independent biological replications. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test. (C) Transfected cells were visualized using high-content imaging. Fluorescent signals: green for anti-NRP1 mAb, blue for Hoechst. (D) Percentage of NRP1-expressing cells normalized to cells transfected with siControl. Data are presented as mean ± SEM from three independent experiments. Statistical analysis was conducted using a paired t-test. Next, siRNA-transfected cells were infected with different variants of SARS-CoV-2. (E) SARS-CoV-2-infected cells were detected using high-content imaging. Fluorescent signals: green for anti-SARS-CoV NP mAb, blue for Hoechst. (F) The fluorescent intensity of NP+ cells was measured. All data represent three independent experiments. Statistical analysis among each group of variant was performed using an unpaired t-test. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Journal: PLOS One

    Article Title: Omicron SARS-CoV-2 shows NRP1-linked susceptibility in adipose-derived MSCs and alters primitive cord blood CD34⁺ HSPCs

    doi: 10.1371/journal.pone.0360439

    Figure Lengend Snippet: (A) Representative western blot depicting the expression of NRP1 in AD-MSCs (No siRNA), cells transfected with non-targeting siRNA (siControl), or siNRP1 for 24 hours. β-actin was used as a loading control. (B) Graph displaying the quantification of NRP1 normalized to β-actin (n = 3). This experiment represents three independent biological replications. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test. (C) Transfected cells were visualized using high-content imaging. Fluorescent signals: green for anti-NRP1 mAb, blue for Hoechst. (D) Percentage of NRP1-expressing cells normalized to cells transfected with siControl. Data are presented as mean ± SEM from three independent experiments. Statistical analysis was conducted using a paired t-test. Next, siRNA-transfected cells were infected with different variants of SARS-CoV-2. (E) SARS-CoV-2-infected cells were detected using high-content imaging. Fluorescent signals: green for anti-SARS-CoV NP mAb, blue for Hoechst. (F) The fluorescent intensity of NP+ cells was measured. All data represent three independent experiments. Statistical analysis among each group of variant was performed using an unpaired t-test. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Article Snippet: To stain the viral NP, a primary rabbit mAb antibody specific for SARS-CoV NP (Sino Biological Inc.) was used at a dilution ratio of 1:1000.

    Techniques: Western Blot, Expressing, Transfection, Control, Analysis, Imaging, Infection, Variant Assay

    (A) Fluorescence intensity of NP-positive UCB-CD34 + HSPCs after infection with WT or Omicron variants of SARS-CoV-2. (B) Infectious viral particle production was determined by the focus-forming assay on Vero-E6/TMPRSS2 cells. (C) HSPC phenotype after infected with SARS-CoV-2 was investigated via the expression of primitive markers through flow cytometry. (D) The representative of HSC phenotype after infected with SARS-CoV-2. (E) Fluorescent intensity of NP-positive UCB-CD34 + HSPCs after infected with heat-inactivated WT and Omicron variant of SARS-CoV-2 compared to active virus. (F) The representative of HSC phenotype after infected with heat-inactivated WT and Omicron compared to active virus. All data are represented as mean ± SEM from three independent biological replicates. Statistical comparisons among Mock, WT, and Omicron in each group were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. For , the unpaired t-test were performed among each group by comparing between Mock vs. WT, Mock vs. Omicron, WT vs. heat-inactivated WT, and Omicron vs. heat-inactivated Omicron. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Journal: PLOS One

    Article Title: Omicron SARS-CoV-2 shows NRP1-linked susceptibility in adipose-derived MSCs and alters primitive cord blood CD34⁺ HSPCs

    doi: 10.1371/journal.pone.0360439

    Figure Lengend Snippet: (A) Fluorescence intensity of NP-positive UCB-CD34 + HSPCs after infection with WT or Omicron variants of SARS-CoV-2. (B) Infectious viral particle production was determined by the focus-forming assay on Vero-E6/TMPRSS2 cells. (C) HSPC phenotype after infected with SARS-CoV-2 was investigated via the expression of primitive markers through flow cytometry. (D) The representative of HSC phenotype after infected with SARS-CoV-2. (E) Fluorescent intensity of NP-positive UCB-CD34 + HSPCs after infected with heat-inactivated WT and Omicron variant of SARS-CoV-2 compared to active virus. (F) The representative of HSC phenotype after infected with heat-inactivated WT and Omicron compared to active virus. All data are represented as mean ± SEM from three independent biological replicates. Statistical comparisons among Mock, WT, and Omicron in each group were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. For , the unpaired t-test were performed among each group by comparing between Mock vs. WT, Mock vs. Omicron, WT vs. heat-inactivated WT, and Omicron vs. heat-inactivated Omicron. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Article Snippet: To stain the viral NP, a primary rabbit mAb antibody specific for SARS-CoV NP (Sino Biological Inc.) was used at a dilution ratio of 1:1000.

    Techniques: Fluorescence, Infection, Focus Forming Assay, Expressing, Flow Cytometry, Variant Assay, Virus

    (A) Representative CFU colonies generated from human UCB-CD34 + HSPCs after exposure to WT or Omicron SARS-CoV-2 compared to Mock. (B) Quantification of burst-forming unit–erythroid (BFU-E), colony-forming unit-granulocyte/macrophage (CFU-GM), and total CFU output (C) Frequency of early erythroid progenitors (CD34 − CD36 ⁺ CD71 ⁺ CD235 − ) following in vitro erythroid differentiation of SARS-CoV-2-exposed CD34 ⁺ cells. (D) CFU output (BFU-E, CFU-GM, and total) in the virus inhibition experiment comparing active versus heat-inactivated virus. (E) Frequency of early erythroid progenitors (CD34 − CD36 ⁺ CD71 ⁺ CD235 − ) in the virus inhibition experiment. The results represent the means and SEM of three independent experiments. For and , the unpaired t-test were performed among each group by comparing of total CFUs, BFU-E, and CFU-GM between Mock vs. WT, Mock vs. Omicron, WT vs. heat-inactivated WT, and Omicron vs. heat-inactivated Omicron. For and , statistical comparisons among Mock, WT, and Omicron in each group were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Journal: PLOS One

    Article Title: Omicron SARS-CoV-2 shows NRP1-linked susceptibility in adipose-derived MSCs and alters primitive cord blood CD34⁺ HSPCs

    doi: 10.1371/journal.pone.0360439

    Figure Lengend Snippet: (A) Representative CFU colonies generated from human UCB-CD34 + HSPCs after exposure to WT or Omicron SARS-CoV-2 compared to Mock. (B) Quantification of burst-forming unit–erythroid (BFU-E), colony-forming unit-granulocyte/macrophage (CFU-GM), and total CFU output (C) Frequency of early erythroid progenitors (CD34 − CD36 ⁺ CD71 ⁺ CD235 − ) following in vitro erythroid differentiation of SARS-CoV-2-exposed CD34 ⁺ cells. (D) CFU output (BFU-E, CFU-GM, and total) in the virus inhibition experiment comparing active versus heat-inactivated virus. (E) Frequency of early erythroid progenitors (CD34 − CD36 ⁺ CD71 ⁺ CD235 − ) in the virus inhibition experiment. The results represent the means and SEM of three independent experiments. For and , the unpaired t-test were performed among each group by comparing of total CFUs, BFU-E, and CFU-GM between Mock vs. WT, Mock vs. Omicron, WT vs. heat-inactivated WT, and Omicron vs. heat-inactivated Omicron. For and , statistical comparisons among Mock, WT, and Omicron in each group were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Article Snippet: To stain the viral NP, a primary rabbit mAb antibody specific for SARS-CoV NP (Sino Biological Inc.) was used at a dilution ratio of 1:1000.

    Techniques: Generated, In Vitro, Virus, Inhibition

    (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Journal: PLOS One

    Article Title: Omicron SARS-CoV-2 shows NRP1-linked susceptibility in adipose-derived MSCs and alters primitive cord blood CD34⁺ HSPCs

    doi: 10.1371/journal.pone.0360439

    Figure Lengend Snippet: (A) Detection of SARS-CoV-2 infected cells using high-content imaging under control conditions. Fluorescent signals: green (anti-SARS-CoV NP mAb), blue (Hoechst). (B) Representative flow cytometry analysis plots showing NP+ cells. (C) Measurement of fluorescent intensity in NP+ cells. (D) Percentage of infected MSCs. (E) The supernatants of infected MSCs were collected and titrated on Vero-E6/TMPRSS2 cells to measure infectious viral particle production using the focus-forming assay. (F) After RNA extraction from infected MSCs, the expression of IDO1 was examined using real-time PCR. The graph displays the expression of IDO1 normalized to GAPDH , with the mock group serving as the control. Data are represented as means ± SEM from three independent biological replicates. For , the Delta condition was available from only two independent donors and was therefore presented descriptively and excluded from the statistical analysis. Statistical comparisons among the remaining groups were performed using one-way ANOVA followed by Tukey’s multiple-comparisons test. One-way ANOVA showed a significant overall difference among groups, F(2, 6) = 6.794, P = 0.0287. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Article Snippet: After that, the plate was stained with 1:2500 of rabbit anti-SARS-CoV NP (Sino Biological Inc.) and then anti-rabbit HRP (DAKO) was used as secondary antibody.

    Techniques: Infection, Imaging, Control, Flow Cytometry, Analysis, Focus Forming Assay, RNA Extraction, Expressing, Real-time Polymerase Chain Reaction

    (A) Representative western blot depicting the expression of NRP1 in AD-MSCs (No siRNA), cells transfected with non-targeting siRNA (siControl), or siNRP1 for 24 hours. β-actin was used as a loading control. (B) Graph displaying the quantification of NRP1 normalized to β-actin (n = 3). This experiment represents three independent biological replications. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test. (C) Transfected cells were visualized using high-content imaging. Fluorescent signals: green for anti-NRP1 mAb, blue for Hoechst. (D) Percentage of NRP1-expressing cells normalized to cells transfected with siControl. Data are presented as mean ± SEM from three independent experiments. Statistical analysis was conducted using a paired t-test. Next, siRNA-transfected cells were infected with different variants of SARS-CoV-2. (E) SARS-CoV-2-infected cells were detected using high-content imaging. Fluorescent signals: green for anti-SARS-CoV NP mAb, blue for Hoechst. (F) The fluorescent intensity of NP+ cells was measured. All data represent three independent experiments. Statistical analysis among each group of variant was performed using an unpaired t-test. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Journal: PLOS One

    Article Title: Omicron SARS-CoV-2 shows NRP1-linked susceptibility in adipose-derived MSCs and alters primitive cord blood CD34⁺ HSPCs

    doi: 10.1371/journal.pone.0360439

    Figure Lengend Snippet: (A) Representative western blot depicting the expression of NRP1 in AD-MSCs (No siRNA), cells transfected with non-targeting siRNA (siControl), or siNRP1 for 24 hours. β-actin was used as a loading control. (B) Graph displaying the quantification of NRP1 normalized to β-actin (n = 3). This experiment represents three independent biological replications. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test. (C) Transfected cells were visualized using high-content imaging. Fluorescent signals: green for anti-NRP1 mAb, blue for Hoechst. (D) Percentage of NRP1-expressing cells normalized to cells transfected with siControl. Data are presented as mean ± SEM from three independent experiments. Statistical analysis was conducted using a paired t-test. Next, siRNA-transfected cells were infected with different variants of SARS-CoV-2. (E) SARS-CoV-2-infected cells were detected using high-content imaging. Fluorescent signals: green for anti-SARS-CoV NP mAb, blue for Hoechst. (F) The fluorescent intensity of NP+ cells was measured. All data represent three independent experiments. Statistical analysis among each group of variant was performed using an unpaired t-test. * P < 0.05, ** P < 0.01, *** P = 0.0001, **** P < 0.0001.

    Article Snippet: After that, the plate was stained with 1:2500 of rabbit anti-SARS-CoV NP (Sino Biological Inc.) and then anti-rabbit HRP (DAKO) was used as secondary antibody.

    Techniques: Western Blot, Expressing, Transfection, Control, Analysis, Imaging, Infection, Variant Assay